Welcome!

News Feed Item

United States Orthobiologics Market Outlook to 2020

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

United States Orthobiologics Market Outlook to 2020

http://www.reportbuyer.com/pharma_healthcare/biotechnology/united_states_orthobiologics_market_outlook_2020.html

United States Orthobiologics Market Outlook to 2020

Summary

GlobalData's new report, "United States Orthobiologics Market Outlook to 2020", provides key market data on the United States Orthobiologics market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Bone Graft Substitutes, Viscosupplementation, Bone Allografts and Bone Growth Stimulators.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Orthobiologics market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size for Orthobiologics market categories - Bone Graft Substitutes, Viscosupplementation, Bone Allografts and Bone Growth Stimulators.
- Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
- 2012 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the United States Orthobiologics market.
- Key players covered include DePuy Companies, Sanofi, Medtronic, Inc., NuVasive, Inc., Biomet, Inc., Smith & Nephew Plc, Baxter International Inc., Wright Medical Group, Inc., Stryker Corporation and Alphatec Holdings, Inc.

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 What Is This Report About? 10
2.2 Orthobiologics Market Segmentation 10
2.3 Definitions of Markets Covered in the Report 11
3 Orthobiologics Market, United States 12
3.1 Orthobiologics Market, United States, Revenue ($m), 2005-2012 12
3.2 Orthobiologics Market, United States, Revenue ($m), 2012-2020 14
3.2.1 Bone Graft Substitutes Market, United States, Revenue ($m), by Segment, 2005-2012 16
3.2.2 Bone Graft Substitutes Market, United States, Revenue ($m), by Segment, 2012-2020 18
3.3 Orthobiologics Market, United States, Volume (Units), 2005-2012 20
3.4 Orthobiologics Market, United States, Volume (Units), 2012-2020 22
3.4.1 Bone Graft Substitutes Market, United States, Volume (Units), by Segment, 2005-2012 24
3.4.2 Bone Graft Substitutes Market, United States, Volume (Units), by Segment, 2012-2020 26
3.5 Orthobiologics Market, United States, Average Price ($), 2005-2020 28
3.6 Orthobiologics Market, United States, Distribution Share by Revenue ($m), 2011-2012 30
3.7 Orthobiologics Market, United States, Company Share by Revenue ($m), 2011-2012 31
4 Overview of Key Companies in United States Orthobiologics Market 33
4.1 Medtronic, Inc. 33
4.1.1 Company Overview 33
4.2 DePuy Companies 33
4.2.1 Company Overview 33
4.3 Sanofi 33
4.3.1 Company Overview 33
4.4 Globus Medical, Inc. 34
4.4.1 Company Overview 34
4.5 NuVasive, Inc. 34
4.5.1 Company Overview 34
4.6 Stryker Corporation 35
4.6.1 Company Overview 35
4.7 DJO Finance LLC 35
4.7.1 Company Overview 35
4.8 Biomet, Inc. 35
4.8.1 Company Overview 35
4.9 Baxter International Inc. 36
4.9.1 Company Overview 36
4.10 Smith & Nephew Plc 36
4.10.1 Company Overview 36
4.11 Anika Therapeutics, Inc. 37
4.11.1 Company Overview 37
4.12 Wright Medical Group, Inc. 37
4.12.1 Company Overview 37
4.13 Seikagaku Corporation 38
4.13.1 Company Overview 38
5 Orthobiologics Market Pipeline Products 39
6 Financial Deals Landscape 41
6.1 Acquisition 41
6.1.1 DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 41
6.2 Asset Transactions 43
6.2.1 Biomet Completes Acquisition Of Trauma Business Of Depuy Orthopaedics For US$280 Million 43
6.3 Debt Offerings 45
6.3.1 Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 45
6.3.2 Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 47
6.3.3 Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 49
6.4 Equity Offerings 51
6.4.1 Integra LifeSciences Completes Public Offering Of Shares For US$161 Million 51
6.4.2 Bacterin International Completes Private Placement Of Shares For US$4.8 Million 53
6.4.3 BioMimetic Therapeutics Files Registration Statement For Public Offering Of Securities For US$150 Million 54
6.4.4 MiMedx Group Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 55
6.4.5 Bacterin International Completes Private Placement Of Shares For US$3.9 Million 56
6.5 Partnerships 57
6.5.1 Artimplant Enters Into Co-Marketing Agreement With Tiller International Capital 57
6.6 Private Equity 58
6.6.1 Bioventus To Raise US$118 Million In Private Equity Financing 58
6.7 Venture Financing 60
6.7.1 Soft Tissue Regeneration Raises US$5 Million In Venture Financing 60
6.7.2 Bone Solutions Raises US$0.04 Million In Venture Financing 62
6.7.3 Soft Tissue Regeneration Raises US$4.7 Million In Venture Financing 63
6.7.4 Tela Bio Raises US$6 Million In Venture Financing 64
6.7.5 Isto Technologies Raises US$2 Million In Venture Financing 65
6.7.6 Tela Bio Raises US$16 Million In Venture Financing 66
6.7.7 AFcell Medical Raises US$2.23 Million In Series A Financing 67
7 Recent Developments 68
7.1 Corporate Communications 68
7.1.1 Jan 09, 2014: ISTO Technologies names George W. Dunbar, Jr. President and Chief Executive Officer 68
7.1.2 Jan 07, 2014: ISTO Technologies Appoints James McGorry to Board of Directors 69
7.1.3 Jan 02, 2014: Alphatec Spine Announces Executive Leadership Changes 69
7.1.4 Jan 02, 2014: Alphatec Spine Announces Executive Leadership Changes 70
7.1.5 Nov 14, 2013: Histogenics announces appointment of John H. Johnson to its board of directors 71
7.1.6 Oct 28, 2013: Histogenics Announces Nancy Lynch, M.D., as CMO 71
7.1.7 Oct 14, 2013: Exactech Names Orthopaedic Executive Bill Shopoff as Vice President U.S. Sales; Industry Veteran Bob Purcell Retires After 40+ Years in Healthcare 72
7.1.8 Sep 25, 2013: Accellent Announces the Promotion of Jeremy Friedman to President and Chief Operating Officer for the Cardio & Vascular Business and the Appointment of Richard Johnson as Interim CFO 72
7.1.9 Aug 27, 2013: Integra LifeSciences Appoints Donald E. Morel, Jr., Ph.D. as a Director and Announces Retirement of Neal Moszkowski as a Director 73
7.1.10 Aug 20, 2013: Histogenics Announces Key Additions to Management Team 73
7.1.11 Jul 23, 2013: Dean Schauer, Executive Vice President, Cardio & Vascular Group, Announces Resignation 74
7.1.12 Jun 10, 2013: Histogenics Appoints Peter Greenleaf As CEO 74
7.1.13 May 16, 2013: Cerapedics Announces Senior Management Changes 75
7.1.14 Mar 18, 2013: Integra LifeSciences Holdings Corporation Announces Changes to Its Board of Directors 76
7.2 Financial Announcements 77
7.2.1 Feb 18, 2014: Medtronic Reports Third Quarter Earnings 77
7.2.2 Jan 30, 2014: Bard Announces Fourth Quarter Results 79
7.2.3 Jan 22, 2014: BIOTRONIK Enrolls First Patients in Expansion of ProMRI Clinical Trial 79
7.2.4 Dec 23, 2013: Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application 81
7.2.5 Dec 11, 2013: Bard Declares Quarterly Dividend 82
7.2.6 Nov 19, 2013: Medtronic Reports Second Quarter Earnings 82
7.2.7 Nov 11, 2013: Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014 84
7.2.8 Nov 07, 2013: Accellent Announces Third Quarter 2013 Results 85
7.2.9 Nov 04, 2013: Wright Medical Group Reports 2013 Third Quarter Financial Results 86
7.2.10 Oct 28, 2013: Integra LifeSciences Reports Third Quarter 2013 Financial Results 87
7.2.11 Oct 23, 2013: Exactech Q3 Net Income up 25% to $3.2 Million; Diluted EPS $0.23 vs. $0.19; Worldwide Sales Up 9% to $55.7 Million; U.S. Sales Increased 11% 89
7.2.12 Oct 22, 2013: Bard Announces Third Quarter Results 90
7.2.13 Oct 11, 2013: Integra LifeSciences to Host Its Third Quarter 2013 Earnings Results Conference Call on October 28, 2013 90
7.2.14 Oct 09, 2013: Bard Declares Quarterly Dividend 90
7.2.15 Oct 08, 2013: Exactech Schedules Third Quarter 2013 Earnings Release and Conference Call 91
7.2.16 Oct 03, 2013: Wright Medical Group to Host Third Quarter 2013 Earnings Conference Call 91
7.2.17 Oct 01, 2013: Bard to Host Earnings Conference Call on October 22, 2013 91
7.2.18 Sep 18, 2013: Avo Photonics Provides Design and Production Services for Optofluidics' NanoTweezer System 91
7.2.19 Sep 09, 2013: ICU Medical's New ChemoLock Needlefree Closed System Transfer Device Receives First-Ever FDA 510(k) Clearances for Both Pharmacy and Patient Administration Applications 92
7.2.20 Aug 22, 2013: Douglasville Nursing and Rehabilitation Center Installs Masimo Patient SafetyNet System for Improved Patient Monitoring 93
7.2.21 Aug 20, 2013: Medtronic Reports First Quarter Earnings 94
7.2.22 Aug 13, 2013: Accellent Announces Second Quarter 2013 Results 95
7.2.23 Aug 12, 2013: Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014 96
7.2.24 Aug 06, 2013: Accellent Announces Timing of Second Quarter 2013 Earnings Release and Conference Call 97
7.2.25 Aug 05, 2013: Wright Medical Group Reports 2013 Second Quarter Financial Results 97
7.2.26 Aug 01, 2013: Integra LifeSciences Reports Second Quarter 2013 Financial Results 99
7.2.27 Jul 24, 2013: Bard Announces Second Quarter Results 100
7.2.28 Jul 24, 2013: Exactech Q2 Net Income up 23% to $3.7 Million. Diluted EPS $0.27 vs. $0.23. Worldwide Sales Up 10% to $60.6 Million. U.S. Sales Increased 13% 100
7.2.29 Jul 10, 2013: Exactech Schedules Second Quarter 2013 Earnings Release and Conference Call 101
7.2.30 Jul 10, 2013: Wright Medical Group, Inc. to Host Second Quarter 2013 Earnings Conference Call 102
7.2.31 Jul 03, 2013: Integra LifeSciences to Host Its Second Quarter 2013 Earnings Results Conference Call on August 1, 2013 102
7.2.32 Jun 14, 2013: Atossa Genetics And HealthSmart Sign Nationwide Agreement For ForeCYTE Breast Health Test 102
7.2.33 Jun 04, 2013: Neuros Medical Announces Pilot Study Results On Electrical Nerve Block Technology 104
7.2.34 May 30, 2013: DiFusion Completes Series Of In Vitro Tests And An In Vivo Study To Validate Efficacy Of Its CleanFuze 104
7.2.35 May 21, 2013: Medtronic Reports Revenue Of $16.6 Billion In Fiscal 2013 105
7.2.36 May 14, 2013: Accellent Reports Revenue Of $120.8m In Q1 2013 107
7.2.37 Apr 30, 2013: Wright Medical Reports Revenue Of $120.4m In Q1 2013 107
7.2.38 Apr 23, 2013: Exactech Reports Revenue Of $59.3m In Q1 2013 109
7.2.39 Apr 16, 2013: Exactech Schedules First Quarter 2013 Earnings Release and Conference Call 109
7.2.40 Apr 10, 2013: Integra LifeSciences to Host Its First Quarter 2013 Earnings Results Conference Call on May 2, 2013 109
7.2.41 Mar 27, 2013: Accellent Reports Revenue Of $498.6m In 2012 110
7.2.42 Feb 26, 2013: Exactech Reports Revenue Of $224.3m In 2012 110
7.2.43 Feb 21, 2013: Integra LifeSciences Reports Revenue Of $830.9m In 2012 111
7.2.44 Feb 21, 2013: Wright Medical Reports Revenue Of $483.8m In 2012 112
7.2.45 Feb 20, 2013: Merck And Samsung Bioepis Enter Biosimilars Development Agreement 114
7.3 Government and Public Interest 115
7.3.1 Jan 06, 2014: Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference 115
7.3.2 Jan 06, 2014: Bard to Host Earnings Conference Call on January 30, 2014 116
7.3.3 Dec 30, 2013: Integra LifeSciences to Participate in the 32nd Annual J.P. Morgan Healthcare Conference 116
7.3.4 Dec 20, 2013: Bard to Present at J.P. Morgan Healthcare Conference 116
7.3.5 Dec 18, 2013: Wright Medical Group to Participate in 32nd Annual J.P. Morgan Healthcare Conference 116
7.3.6 Dec 04, 2013: Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference 116
7.3.7 Nov 26, 2013: ISTO To Present At Upcoming Conferences 116
7.3.8 Nov 26, 2013: Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference 117
7.3.9 Nov 20, 2013: Bard to Present at Piper Jaffray Healthcare Conference 117
7.3.10 Nov 18, 2013: Integra LifeSciences to Participate in the Piper Jaffray Healthcare and Oppenheimer Healthcare Conferences in December 117
7.3.11 Nov 12, 2013: Wright Medical Group to Participate in 25th Annual Piper Jaffray Healthcare Conference 117
7.3.12 Oct 29, 2013: Bard to Present at Credit Suisse Healthcare Conference 118
7.3.13 Oct 28, 2013: Wright Medical to Participate in Credit Suisse 2013 Healthcare Conference 118
7.3.14 Sep 10, 2013: Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th 118
7.3.15 Sep 06, 2013: Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference 118
7.3.16 Sep 03, 2013: Bard to Host Conference Call on September 4, 2013 118
7.3.17 Aug 29, 2013: Integra LifeSciences to Participate in Investor Conferences in September 118
7.3.18 Aug 21, 2013: Wright Medical Group to Participate in Baird 2013 Health Care Conference 119
7.3.19 Aug 20, 2013: Bard to Present at Morgan Stanley Global Healthcare Conference 119
7.3.20 Aug 20, 2013: Wright Medical Group to Participate in Morgan Stanley Global Healthcare Conference 119
7.3.21 Aug 06, 2013: Exactech Announces Investor Presentation at Canaccord Genuity Growth Conference 119
7.3.22 May 29, 2013: Integra LifeSciences to Participate in Investor Conferences in June 119
7.3.23 May 07, 2013: Integra LifeSciences to Participate in Investor Conferences in May 120
7.3.24 Mar 05, 2013: Integra LifeSciences to Participate in Investor Conferences in March 120
7.4 Legal And Regulatory 120
7.4.1 Feb 11, 2014: Alphatec Spine Announces Jury Verdict in the OrthoTec Litigation 120
7.4.2 Jan 28, 2014: 3-D Matrix Files Patent Infringement Complaint Against Menicon and B-Bridge International 121
7.4.3 Jan 22, 2014: Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures 121
7.4.4 Oct 19, 2013: Medtronic Statement on Medical Device Security 122
7.4.5 Sep 26, 2013: Integra LifeSciences Announces Resolution of Warning Letter Related to Its Plainsboro, NJ, Manufacturing Facility 123
7.4.6 Aug 01, 2013: Medtronic Notifies More Than 2,700 Patients Of Lost Records 123
7.4.7 Jul 01, 2013: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Medtronic, Inc. 123
7.5 Other Significant Developments 124
7.5.1 Feb 13, 2014: Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014 124
7.5.2 Jan 28, 2014: Medtronic Relocates Its Regional Headquarters to Dubai 124
7.5.3 Dec 16, 2013: Genzyme and NORD Establish Program to Help Undiagnosed Patients with Rare Diseases 125
7.5.4 Dec 09, 2013: Launch of NuCollagen to Supply Laboratory and Medical Grade Bovine Collagen 126
7.5.5 Dec 04, 2013: Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles 126
7.5.6 Oct 23, 2013: Integra LifeSciences Announces Update on Optimization Initiatives 128
7.5.7 Aug 22, 2013: Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014 129
7.5.8 Aug 12, 2013: Small Bone Innovations Launches New Charcot Solution Website 129
7.6 Product News 130
7.6.1 Dec 05, 2013: Physicians Discover New Knee Ligament 130
7.6.2 Nov 15, 2013: FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall 130
7.6.3 Sep 23, 2013: Vista Equity Partners Completes Acquisition Of Majority Interest In Greenway Medical Technologies For US$555.3 Million In Going Private Transaction 131
7.6.4 May 23, 2013: RTI Biologics Passes Five Million Mark In Distributing Implants Sterilized With Zero Incidence Of Implant Associated Infection 133
7.6.5 Apr 29, 2013: Advanced Biologics Adds More Patient Results Showcasing OsteoAMP's Superior Fusion Rates Compared To rhBMP-2 133
7.6.6 Mar 19, 2013: Ranier Technology Gets US Patent For Graduated Modulus Technology 134
7.7 Strategy And Business Planning 134
7.7.1 Sep 17, 2013: Medtronic Opens New Customer Innovation Centre in Galway, Ireland 134
7.7.2 Sep 02, 2013: Medtronic announces formation of hospital solutions business aimed at driving efficiencies 135
7.7.3 Aug 29, 2013: Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation 136
8 Appendix 137
8.1 Research Methodology 138
8.1.1 Coverage 138
8.1.2 Secondary Research 138
8.1.3 Primary Research 139
8.1.4 Market Modeling and Forecasting 140
8.1.5 Company Share Analysis 143
8.1.6 Distribution Share Analysis 144
8.2 Expert Panel 145
8.3 GlobalData Consulting 145
8.4 Contact Us 145
8.5 Disclaimer 145

List of Tables

Table 1: Orthobiologics Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 13
Table 2: Orthobiologics Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 15
Table 3: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 17
Table 4: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 19
Table 5: Orthobiologics Market, United States, Volume (Units), Historic, 2005-2012 21
Table 6: Orthobiologics Market, United States, Volume (Units), Forecast, 2012-2020 23
Table 7: Bone Graft Substitutes Market, United States, Volume (Units), Historic, 2005-2012 25
Table 8: Bone Graft Substitutes Market, United States, Volume (Units), Forecast, 2012-2020 27
Table 9: Orthobiologics Market, United States, Average Price ($), Historic, 2005-2012 28
Table 10: Orthobiologics Market, United States, Average Price ($), Forecast, 2012-2020 29
Table 11: Orthobiologics Market, United States, Distribution Share by Revenue ($m), USD Constant, 2011-2012 30
Table 12: Orthobiologics Market, United States, Company Share by Revenue ($m), USD Constant, 2011-2012 32
Table 13: Orthobiologics Market Pipeline Products 39
Table 14: DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 41
Table 15: Biomet Completes Acquisition Of Trauma Business Of Depuy Orthopaedics For US$280 Million 43
Table 16: Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 45
Table 17: Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 47
Table 18: Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 49
Table 19: Integra LifeSciences Completes Public Offering Of Shares For US$161 Million 51
Table 20: Bacterin International Completes Private Placement Of Shares For US$4.8 Million 53
Table 21: BioMimetic Therapeutics Files Registration Statement For Public Offering Of Securities For US$150 Million 54
Table 22: MiMedx Group Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 55
Table 23: Bacterin International Completes Private Placement Of Shares For US$3.9 Million 56
Table 24: Artimplant Enters Into Co-Marketing Agreement With Tiller International Capital 57
Table 25: Bioventus To Raise US$118 Million In Private Equity Financing 58
Table 26: Soft Tissue Regeneration Raises US$5 Million In Venture Financing 60
Table 27: Bone Solutions Raises US$0.04 Million In Venture Financing 62
Table 28: Soft Tissue Regeneration Raises US$4.7 Million In Venture Financing 63
Table 29: Tela Bio Raises US$6 Million In Venture Financing 64
Table 30: Isto Technologies Raises US$2 Million In Venture Financing 65
Table 31: Tela Bio Raises US$16 Million In Venture Financing 66
Table 32: AFcell Medical Raises US$2.23 Million In Series A Financing 67
Table 33: Total Number of Primary Research Participants, Orthopedic Devices Market, by Country 140

List of Figures

Figure 1: Orthobiologics Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 12
Figure 2: Orthobiologics Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 14
Figure 3: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 16
Figure 4: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 18
Figure 5: Orthobiologics Market, United States, Volume (Units), Historic, 2005-2012 20
Figure 6: Orthobiologics Market, United States, Volume (Units), Forecast, 2012-2020 22
Figure 7: Bone Graft Substitutes Market, United States, Volume (Units), Historic, 2005-2012 24
Figure 8: Bone Graft Substitutes Market, United States, Volume (Units), Forecast, 2012-2020 26
Figure 9: Orthobiologics Market, United States, Company Share (%), 2012 31
Figure 10: GlobalData Epidemiology-Based Forecasting Model 142
Figure 11: GlobalData Capital Equipment-Based Forecasting Model 143
Figure 12: Primary Interviews by Participant Type (%) 144

Read the full report:
United States Orthobiologics Market Outlook to 2020

http://www.reportbuyer.com/pharma_healthcare/biotechnology/united_states_orthobiologics_market_outlook_2020.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
"MobiDev is a Ukraine-based software development company. We do mobile development, and we're specialists in that. But we do full stack software development for entrepreneurs, for emerging companies, and for enterprise ventures," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
Is it possible to migrate 100% of your data ecosystem to the cloud? Join Joe Caserta as he takes you on a complete journey to digital transformation mapping out on-prem data footprint and walking it to the cloud. Joe will also explain how the modern ecosystem supports Artificial Intelligence and will include business use cases to back each of his insights.
Your job is mostly boring. Many of the IT operations tasks you perform on a day-to-day basis are repetitive and dull. Utilizing automation can improve your work life, automating away the drudgery and embracing the passion for technology that got you started in the first place. In this presentation, I'll talk about what automation is, and how to approach implementing it in the context of IT Operations. Ned will discuss keys to success in the long term and include practical real-world examples. Ge...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...